Adults 18 to 65 years of age with Major Depressive Disorder (MDD) may qualify for a clinical research study evaluating an investigational medication.
MDD Study
Age Range:
18 to 65
Gender:
Male and Female
Location:
Media, Pennsylvania
About the Study
Researchers are conducting a Phase 2 clinical research study to evaluate the safety, tolerability, and effectiveness of an investigational medication called SPT-300 in adults with Major Depressive Disorder, with or without anxious distress. Participants will receive either the investigational medication or a placebo (a capsule that contains no active medication) in a 1:1 ratio.
Qualifications
You May Qualify If You:
- Are 18 to 65 years of age
- Have a primary diagnosis of Major Depressive Disorder (MDD)
- Are currently experiencing a depressive episode that has lasted at least 4 weeks, but no longer than 18 months
- Have a history of recurrent depression
- Are willing to attend weekly study visits and complete study procedures
Additional eligibility criteria apply.
FEATURED STUDIES
Weight Loss Research Study
Adults with overweight or obesity who do not have type 2 diabetes may qualify for a clinical research study evaluating
Heart Disease & Inflammation Study
Adults 18 years of age and older with elevated inflammation levels and heart disease or certain health conditions that increase
Heart Failure Prevention Study
Researchers are evaluating an investigational treatment for adults who have type 2 diabetes and cardiovascular disease and may be at
Weight & Wellness Research Study Interest
Researchers are evaluating an investigational oral treatment for adults who are overweight and may be at risk of developing certain
Flu Prevention Study – Higher-Risk Individuals
Researchers are evaluating an investigational medication that may help prevent the flu in people who are at higher risk of
General Anxiety Disorder Study
Individuals with generalized anxiety disorder (GAD) who experience ongoing worry, stress, or difficulty managing anxiety symptoms may qualify for a